Colin Weekes教授在波士頓哈佛醫(yī)學院的血液學/腫瘤學系任職，同時是麻省總醫(yī)院Tucker Gosnell胃腸癌中心胰腺癌醫(yī)學腫瘤研究主任，專注于胰腺癌患者的臨床和轉(zhuǎn)化研究，他所帶領(lǐng)的研究小組的目標是將生物學原理納入胰腺癌患者的治療中。目前他正在與基礎(chǔ)科學家合作，旨在將靶向治療和疾病反應的生物標志物整合到臨床試驗開發(fā)中。

除了從事胰腺癌的工作外，Weekes博士還致力于胃腸道惡性腫瘤的早期藥物開發(fā)。他的臨床興趣包括胰腺癌，結(jié)腸癌和直腸癌，以及肝癌，包括膽管癌和肝細胞癌。他可以治療多種類型的癌癥患者，包括結(jié)腸直腸癌，食道癌，膽囊癌，胃腸道癌，肝癌和胃癌。

履歷

Colin Weekes教授畢業(yè)于美國內(nèi)布拉斯加大學醫(yī)學中心(UNMC)，并在UNMC獲得了兩個碩士學位(1998年在UNMC獲得博士學位，2000年獲得醫(yī)學學位)。作為UNMC的優(yōu)秀學員，2018年Colin Weekes教授被邀請出席12月12日的UNMC研究生榮譽大會，并在大會發(fā)表了演講。

正在UNMC研究生榮譽大會演講的Colin Weekes教授

圖源：unmc.edu

醫(yī)學院畢業(yè)后，Colin Weekes教授成為了阿拉巴馬大學醫(yī)學院內(nèi)科住院醫(yī)師，并獲得獲得約翰·霍普金斯醫(yī)院(Johns Hopkins Hospital)醫(yī)學腫瘤學研究金，該研究金專注于開發(fā)胰腺癌新療法的轉(zhuǎn)化研究。

之后，Colin Weekes教授在科羅拉多丹佛大學安舒茲醫(yī)學校園的腫瘤內(nèi)科任教。

2017年，Colin Weekes教授加入麻省總醫(yī)院，成為了麻省總醫(yī)院Tucker Gosnell胃腸癌中心胰腺癌醫(yī)學腫瘤研究主任。

成就

約翰·霍普金斯醫(yī)院(Johns Hopkins Hospital)醫(yī)學腫瘤學研究金

美國內(nèi)科醫(yī)學委員會認證

醫(yī)學腫瘤學認證

美國臨床腫瘤學會(ASCO)活躍成員

美國癌癥研究協(xié)會(AACR)活躍成員

專業(yè)領(lǐng)域

胰腺癌、結(jié)腸和直腸癌、膽管癌、肝細胞癌、臨床試驗，開發(fā)新藥組合、新藥的臨床試驗

部分著作

Michelakos T, Cai L, Villani V, Sabbatino F, Kontos F, Fernández-Del Castillo C, Yamada T, Neyaz A, Taylor MS, Deshpande V, Kurokawa T, Ting DT, Qadan M, Weekes CD, Allen JN, Clark JW, Hong TS, Ryan DP, Wo JY, Warshaw AL, Lillemoe KD, Ferrone S, Ferrone CR. Tumor microenvironment immune response in pancreatic ductal adenocarcinoma patients treated with neoadjuvant therapy. Journal of the National Cancer Institute 2020.

Rodrigues C, Hank T, Qadan M, Ciprani D, Mino-Kenudson M, Weekes CD, Ryan DP, Clark JW, Allen JN, Hong TS, Wo JY, Ferrone CR, Warshaw AL, Lillemoe KD, Fernandez-Del Castillo C. Impact of adjuvant therapy in patients with invasive intraductal papillary mucinous neoplasms of the pancreas. Pancreatology 2020.

Parikh AR, Mojtahed A, Schneider JL, Kanter K, Van Seventer EE, Fetter IJ, Thabet A, Fish MG, Teshome B, Fosbenner K, Nadres B, Shahzade HA, Allen JN, Blaszkowsky LS, Ryan DP, Giantonio B, Goyal L, Nipp RD, Roeland E, Weekes CD, Wo JY, Zhu AX, Dias-Santagata D, Iafrate AJ, Lennerz JK, Hong TS, Siravegna G, Horick N, Clark JW, Corcoran RB. Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. Clin Cancer Res 2020.

Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, Drapek LC, Ly L, Baglini CV, Blaszkowsky LS, Ferrone CR, Parikh AR, Weekes CD, Nipp RD, Kwak EL, Allen JN, Corcoran RB, Ting DT, Faris JE, Zhu AX, Goyal L, Berger DL, Qadan M, Lillemoe KD, Talele N, Jain RK, DeLaney TF, Duda DG, Boucher Y, Fernández-Del Castillo C, Hong TS. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. JAMA Oncol 2019.

Strickler JH, Weekes CD, Nemunaitis J, Ramanathan RK, Heist RS, Morgensztern D, Angevin E, Bauer TM, Yue H, Motwani M, Parikh A, Reilly EB, Afar D, Naumovski L, Kelly K. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. J Clin Oncol 2018.

Davis SL, Eckhardt SG, Diamond JR, Messersmith WA, Dasari A, Weekes CD, Lieu CH, Kane M, Choon Tan A, Pitts TM, Leong S. A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer. Oncologist 2018.

Weekes CD, Rosen LS, Capasso A, Wong KM, Ye W, Anderson M, McCall B, Fredrickson J, Wakshull E, Eppler S, Shon-Nguyen Q, Desai R, Huseni M, Hegde PS, Pourmohamad T, Rhee I, Bessudo A. Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol 2018.

Weekes CD, Clark JW, Zhu AX. Tivantinib for advanced hepatocellular carcinoma: is MET still a viable target? Lancet Oncol. 2018; 19:591-592.

Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017; 15:1028-1061.

Bendell JC, Javle M, Bekaii-Saab TS, Finn RS, Wainberg ZA, Laheru DA, Weekes CD, Tan BR, Khan GN, Zalupski MM, Infante JR, Jones S, Papadopoulos KP, Tolcher AW, Chavira RE, Christy-Bittel JL, Barrett E, Patnaik A. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. Br J Cancer 2017; 116:575-583.

Kendrick AA, Schafer J, Dzieciatkowska M, Nemkov T, D'Alessandro A, Neelakantan D, Ford HL, Pearson CG, Weekes CD, Hansen KC, Eisenmesser EZ. CD147: a small molecule transporter ancillary protein at the crossroad of multiple hallmarks of cancer and metabolic reprogramming. 2018; 8:6742-6762.